View Cart  

Novartis Wins Advisory Panel Support for Approval of Tobi Alternative

A A
The FDA’s Anti-Infective Drugs Advisory Committee has recommended the FDA approve Novartis’ inhaler-based version of cystic fibrosis (CF) drug Tobi.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00